tbuckley/cabot-search huggingface dataset:
Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group
Authors: Dennis A. Eichenauer, Helen Goergen, Annette Pluetschow, Karolin Behringer, Stefanie Kreissl, Paul Bröckelmann, Michael Fuchs, Boris Böll, Bastian von Tresckow, Peter Borchmann, Andreas Engert
Journal: Blood (2015)
Human Embryonic Stem Cell-Derived “NET-Like” Structure Serves as a Hematopoietic Progenitor Niche and Favors Generation of Mature Megakaryocytes and Functional Platelets.
Authors: Naoya Takayama, Hidekazu Nishikii, Takashi Hiroyama, Yukio Nakamura, Hiroko Tsukui, Koji Eto, Hiromitsu Nakauchi
Journal: Blood (2006)
Ninlaro (ixazomib) and Brentuximab Vedotin (ADCETRIS) Combination Results in Synergistic Antitumor Activity in Mouse Models of CD30 Positive Anaplastic Large Cell Lymphoma
Authors: Nibedita Chattopadhyay, Sakeena Syed, Yuhong Zhang, Jie Yu, Dan He McDougall, Lunyin Yu Yu, Stephen Tirrell, Allison Berger, Helgi van de Velde, Christopher Tremblay, Dirk Huebner
Journal: Blood (2016)
EDOXABAN VERSUS WARFARIN IN ATRIAL FIBRILLATION ABLATION: FIRST EXPERIENCE FROM THE ENGAGE AF TIMI 48 TRIAL
Authors: Jan Steffel, Christian Ruff, Rose Hammershock, Sabina Murphy, Hans Lanz, Michele Mercuri, Elliott Antman, Eugene Braunwald, Robert Giugliano
Journal: Journal of the American College of Cardiology (2017)
Erratum: The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis
Authors: S Hadano, C Hand, H Osuga, Y Yanagisawa, A Otomo, R Devon, N Miyamoto, J Showguchi-Miyata, Y Okada, R Singaraja, D Figlewicz, T Kwiatkowski, B Hosler, T Sagie, J Skaug, J Nasir, R Brown, S Scherer, G Rouleau, M Hayden, J-E Ikeda, Y Yang, A Hentati, H-X Deng, O Dabbagh, T Sasaki, M Hirano, W-Y Hung, K Ouahchi, J Yan, A Azim, N Cole, G Gascon, A Yagmour, M Ben-Hamida, M Pericak-Vance, T Siddique, P Avner, T Bruls, I Poras, L Eley, S Gas, Patricia Ruiz, V Wiles, R Sousa-Nunes, R Kettleborough, J Morrisette, L Bentley, M Goldsworthy, A Haynes, E Herbert, L Southam, H Lehrach, J Weissenbach, G Manenti, P Rodriguez-Tome, R Beddington, R Cox
Journal: Nature Genetics (2001)
In lieu of cisplatin: Concurrent capecitabine and radiation therapy in the treatment of elderly patients with urothelial cancer
Authors: B. Patel, R. Tripathi, A. Frazier, J. Forman, E. Pontes, J. Fontana, U. N. Vaishampayan
Journal: Journal of Clinical Oncology (2004)

8165 Background: Concurrent cisplatin and external-beam radiation (RT) is a therapeutic option for patients (pts) with localized or locally advanced urothelial cancer (UC) who are not surgical candidates. Elderly pts often poorly tolerate cisplatin. Capecitabine (CA), an oral fluropyrimidine, has been shown to be synergistic with RT in pre-clinical models. Methods: We conducted a retrospective review at our center of 12 pts with UC who due to a poor performance status or co-morbid conditions were precluded from being treated with cisplatin. CA was given at a median dose of 1600 mg/m2 (range: 1200–1800). Concurrent RT of 40–45 Gy was given using 4-field technique to a small pelvic field with a boost to a total of 54–67 Gy (daily fractions of 1.8–2 Gy). Results: Median age was 80 years (range: 46–88) and 4/12 pts had a performance status of 3 or higher. 9/12 pts had localized (T2N0M0) disease and 3/12 pts had locally advanced disease. 5/12 pts required dose modification during their CA treatment due to grade 2 or higher toxicities (diarrhea 3/5, fatigue 2/5, myelosupression 1/5) or worsening of a co-morbid condition. Median dose of RT was 66 Gy in pts finishing prescribed RT and 3/12 pts did not complete RT as planned because of worsening of a co-morbid condition, disease progression and grade 3 diarrhea. Grade 3 toxicities were seen in 4/12 pts, which were diarrhea in 2/12, non-neutropenic infection in 1/12 and lymphocytopenia in 1/12 pts. No severe myelosupression or hand foot syndrome was seen. Clinical complete response was seen in 6/8(75%) evaluable pts who finished prescribed RT. Partial response was observed in 1/8 patient. At a median follow up of 12 months only 1/6 responders have relapsed distally. 4/12 pts died; 1 from lung cancer, 1 from a co-morbidity, and 2 from progressive disease. Conclusions:Concurrent CA and RT is well-tolerated and achieves effective palliation in localized and locally advanced UC offering an alternative to cisplatin in elderly pts with significant co-morbidities. This regimen should be further investigated in prospective trials. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche
Early Response to a Short Course of Induction Chemotherapy Overcomes the Prognostic Role of IPI in Patients with Aggressive NHL. Preliminary Results of the GISL LA05 Trial.
Authors: Nicola Di Renzo, Stefano Luminari, Antonella Montanini, Mario Petrini, Maura Brugiatelli, Paolo G. Gobbi, Caterina Stelitano, Francesco Angrilli, Maurizio Musso, Luca Baldini, Patrizio Mazza, Elsa Pennese, Massimo Federico
Journal: Blood (2006)
A phase 1 study of weekly, divided dose perifosine in patients (pts) with non-small cell lung cancer (NSCLC)
Authors: I. C. Henderson, D. R. Spigel, J. J. Nemunaitis, D. A. Richards, J. E. Liebmann, W. T. Purcell, R. Birch, L. R. Gardner, H. A. Burris III
Journal: Journal of Clinical Oncology (2006)

13063 Background: Perifosine (P) is known to modulate signal transduction pathways, including Akt which is frequently constitutively activated in NSCLC. The half life of P is ∼100 hours and GI toxicities are dose limiting. Studies of a single dose weekly regimen found that the maximum tolerated dose (MTD) was 800 mg. This study was undertaken to see if a higher MTD could be reached using divided doses in NSCLC patients. Methods: Twenty NSCLC patients (pts) were given P, 300 mg, at intervals of 4–6 hours with no more than 4 doses in a 24 hour period. The starting dose was 900 mg and this was escalated by 300 mg/week in subsequent pts to an MTD of 1800 mg. Results: The median age of pts was 62 (range 39–79); 9 were male and median ECOG performance status was 1 (range 0–1). Nineteen pts had received prior chemotherapy (median 2 regimens) and 18 prior radiotherapy. Three pts were entered at each dose and the cohort expanded to 6 pts if 1 or more experienced a grade 3/4 non-hematologic toxicity (DLT) during the first week of therapy. A dose level was toxic if 2 or more pts experienced a DLT. The median time on study was 8 weeks (range 2–28). Seventy-seven percent of pts had no dose reduction (85% of those on 900 mg, 95% on 1200, 72% on 1500, and 78% on 1800 mg). In cohort 1, one pt died within a week without toxicity from P and 1 pt experienced grade 3 nausea, so this cohort was expanded. The other pts in the cohort had no toxicity. In cohort 4 one pt. took 300 mg daily for 6 days and was considered inevaluable. In cohort 3, grade 3/4 toxicity was not observed until after day 28 in 3 pts. Fifteen pts were evaluable for response; 1 had an unconfirmed partial response and 2 had stable disease. Conclusions: This study demonstrated that higher doses of P can be administered on a weekly schedule with divided doses. Weekly doses of 900 and 1200 mg lead to almost no toxicity in most pts. This study has been expanded to a phase 2 trial with direct comparison of weekly and daily doses. The grade 3/4 toxicities for each cohort are given in the table below. [Table: see text] [Table: see text]
Alternatively spliced mu opioid receptor C termini impact the diverse actions of morphine
Authors: Jin Xu, Zhigang Lu, Ankita Narayan, Valerie P. Le Rouzic, Mingming Xu, Amanda Hunkele, Taylor G. Brown, William F. Hoefer, Grace C. Rossi, Richard C. Rice, Arlene Martínez-Rivera, Anjali M. Rajadhyaksha, Luca Cartegni, Daniel L. Bassoni, Gavril W. Pasternak, Ying-Xian Pan
Journal: Journal of Clinical Investigation (2017)

Extensive 3' alternative splicing of the mu opioid receptor gene OPRM1 creates multiple C-terminal splice variants. However, their behavioral relevance remains unknown. The present study generated 3 mutant mouse models with truncated C termini in 2 different mouse strains, C57BL/6J (B6) and 129/SvEv (129). One mouse truncated all C termini downstream of Oprm1 exon 3 (mE3M mice), while the other two selectively truncated C-terminal tails encoded by either exon 4 (mE4M mice) or exon 7 (mE7M mice). Studies of these mice revealed divergent roles for the C termini in morphine-induced behaviors, highlighting the importance of C-terminal variants in complex morphine actions. In mE7M-B6 mice, the exon 7-associated truncation diminished morphine tolerance and reward without altering physical dependence, whereas the exon 4-associated truncation in mE4M-B6 mice facilitated morphine tolerance and reduced morphine dependence without affecting morphine reward. mE7M-B6 mutant mice lost morphine-induced receptor desensitization in the brain stem and hypothalamus, consistent with exon 7 involvement in morphine tolerance. In cell-based studies, exon 7-associated variants shifted the bias of several mu opioids toward β-arrestin 2 over G protein activation compared with the exon 4-associated variant, suggesting an interaction of exon 7-associated C-terminal tails with β-arrestin 2 in morphine-induced desensitization and tolerance. Together, the differential effects of C-terminal truncation illustrate the pharmacological importance of OPRM1 3' alternative splicing.
A META-ANALYSIS OF CONTEMPORARY LESION MODIFICATION STRATEGIES DURING PERCUTANEOUS CORONARY INTERVENTION IN 244,665 PATIENTS FROM 21 STUDIES
Authors: Barbara Anna Danek, Aris Karatasakis, Judit Karacsonyi, Waleed Alharbi, Michele Roesle, Bavana Rangan, M. Nicholas Burke, Subhash Banerjee, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2017)
Minimal Residual Disease Detection Identifies Differences between the Risk Groups Defined by the ALL IC-BFM 2002 and the ALL-BFM 2000 Protocols.
Authors: Eva Fronkova, Leona Reznickova, Katerina Muzikova, Ester Mejstrikova, Ondrej Hrusak, Martin Schrappe, Jan Stary, Jan Trka
Journal: Blood (2004)
HYPEREMIC SUBENDOCARDIAL-TO-SUBEPICARDIAL PERFUSION RATIO AS A SURROGATE MARKER FOR CORONARY ENDOTHELIAL DYSFUNCTION: INITIAL RESULTS IN WOMEN WITH MICROVASCULAR DYSFUNCTION
Authors: Behzad Sharif, Ahmed Al Badri, Janet Wei, Babak Azarbal, Bruce Samuels, Debiao Li, Daniel Berman, C. Noel Bairey Merz
Journal: Journal of the American College of Cardiology (2017)
Pharmacokinetics of synthadotin (ILX651), a novel tubulin polymerization inhibitor, in patients with solid tumors
Authors: P. Bonate, S. Ebbinghaus, J. P. Eder, A. Mita, E. Rubin, C. C. Cunningham, E. K. Rowinsky, E. Hersh, A. R. Craig, L. A. Hammond
Journal: Journal of Clinical Oncology (2004)

2082 Background: Synthadotin (ILX651) is a pentapeptide with a unique mechanism of action that potentially differs from that of microtubule stabilizers (taxanes and epothilones) and tubulin inhibitors (vinca alkaloids and dolastatins) and is postulated to inhibit microtubule nucleation. The drug has been chemically modified to provide improved pharmacological properties and has a therapeutic window potentially enhanced over previous generations of dolastatins. Methods: Synthadotin was administered once-daily to 36 patients daily x5 for 3 weeks every 4 weeks (Study 101) and to 31 patients every other day for 5 days every 3 weeks (Study 102). Doses ranged from 2.3 to 36.3 mg/m2 in Study 101 and 3.9 to 45.7 mg/m2 in Study 102. Blood and urine samples were collected for bioanalysis on Day 1 and 5 of Cycle 1. Synthadotin pharmacokinetics were characterized using noncompartmental methods. Linear mixed effects models were used to relate pharmacokinetic parameters to the following patient covariates: race, sex, age, BSA, dose, and baseline bilirubin, SGOT, SGPT, and creatinine (Cr). Results: AUC(0-∞) was not dose proportional but was time invariant. A 2-fold increase in dose resulted in a 2.3-fold increase in AUC(0-∞). Cmax was dose proportional and time invariant. CL was modeled as: CL (L/h) = 29.1*(BSA in m2)0.56*(Dose in mg/m2)-0.015*(Cr in mg/dL)-0.38. Vss was 22 L and independent of dose. Synthadotin half-life was dose-dependent but was less than 1 hour across all doses. Between-subject (BSV)/inter-occasion variability (IOV) on CL and Vss were 33%/4% and 41%/4%, respectively. Renal elimination was minimal with <15% of the dose excreted in urine. No accumulation was observed with once daily dosing. Conclusions: Synthadotin exhibited dose nonlinearity and was rapidly cleared from plasma with minor renal clearance. BSV was moderate, while IOV variability was smaller. Dosing should continue to be based on BSA because of the positive effect between BSA and CL. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration ILEX Products, Inc. an affiliate of ILEX Oncology ILEX Products, Inc. an affiliate of ILEX Oncology ILEX Oncology, Inc. ILEX Products, Inc. an affiliate of ILEX Oncology ILEX Products, Inc. an affiliate of ILEX Oncology ILEX Products, Inc. an affiliate of ILEX Oncology ILEX Products, Inc. an affiliate of ILEX Oncology
IDENTIFYING NOVEL PHENOTYPES OF ACUTE DECOMPENSATED HEART FAILURE USING CLUSTER ANALYSIS OF CLINICAL VARIABLES
Authors: Yu Horiuchi, Shuzou Tanimoto, Mahbub Latif, Kevin Urayama, Kazuyuki Yahagi, Jiro Aoki, Hiroyoshi Nakajima, Kazuhiro Hara, Kengo Tanabe
Journal: Journal of the American College of Cardiology (2017)
OUTCOMES IN PATIENTS WITH DIABETES MELLITUS AND SUSPECTED CORONARY ARTERY DISEASE FOLLOWING NON-INVASIVE TESTING: INSIGHTS FROM THE PROMISE TRIAL (PROSPECTIVE MULTICENTER IMAGING STUDY FOR EVALUATION OF CHEST PAIN)
Authors: Abhinav Sharma, Nishant Sekaran, Adrian Coles, Neha Pagidipati, Daniel Mark, Kerry Lee, Hussein Al-Khalidi, Michael T. Lu, Udo Hoffmann, Pamela Douglas
Journal: Journal of the American College of Cardiology (2017)
Keap1-Nrf2 System: Potential Role in Prevention of Sickle Cell Disease Organs Damages and Inflammation
Authors: Nadine Keleku-Lukwete, Mikiko Suzuki, Akihito Otsuki, Kouhei Tsuchida, Saori Katayama, Makiko Hayashi, Eriko Naganuma, Takashi Moriguchi, Osamu Tanabe, James Doug Engel, Masue Imaizumi, Masayuki Yamamoto
Journal: Blood (2015)
CURRENT MORE IMPORTANT THAN PAST: INTERPRETING SERIAL HEART FAILURE SPECIFIC HEALTH STATUS IN HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION
Authors: Yashashwi Pokharel, Yevgeniy Khariton, Michael Nassif, Yuanyuan Tang, Philip Jones, Suzanne Arnold, John Spertus
Journal: Journal of the American College of Cardiology (2017)
EXPERIENCE WITH APPLICATION OF 2014 AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION GUIDELINE FOR PRE-OPERATIVE CARDIOVASCULAR EVALUATION FOR NON-CARDIAC SURGERY IN THE PRIMARY CARE SETTING
Authors: Justin Ugwu, Snehal Shrivastava, Tejasvi Sunkara, Jonathon Ross
Journal: Journal of the American College of Cardiology (2017)
HEMOCONCENTRATION DURING MANAGEMENT OF PATIENTS WITH ACUTE HEART FAILURE AND CARDIORENAL SYNDROME: INSIGHTS FROM CARRESS-HF
Authors: Stephen Greene, G. Michael Felker, Jie Sun, Andrew Ambrosy, Bradley Bart, Javed Butler, Adam DeVore, Marat Fudim, Adrian Hernandez, Steven McNulty, Robert Mentz
Journal: Journal of the American College of Cardiology (2017)
Researchers Find Discrepancies in Gene Panel Tests for Cancer
Authors: Charlie Schmidt
Journal: JNCI Journal of the National Cancer Institute (2017)

People are really interested in this work," Korde said."Coming up with a cocktail of targeted drug agents is great.But if a patient falls apart, that alone isn't going to work, so clinicians are interested in looking at what else is out there.Remote monitoring should be one of our most fundamental next reaches: If there is no cure, we must understand all the different aspects of helping a patient improve quality of life."
Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL)
Authors: Deborah A. Thomas, Susan O'Brien, Michael Rytting, Farhad Ravandi, Elias Jabbour, Alessandra Ferrajoli, Zeev Estrov, Guillermo Garcia-Manero, Jan A. Burger, William Wierda, Marina Konopleva, Michael Andreeff, Steven M. Kornblau, Srdan Verstovsek, Gautam Borthakur, Tapan Kadia, Rebecca Garris, Naveen Pemmaraju, Naval Daver, Nitin Jain, Jorge Cortes, Hagop M. Kantarjian
Journal: Blood (2014)
ANTICOAGULATION PROTOCOL AFTER RADIOFREQUENCY ABLATION OF INFARCT-RELATED VENTRICULAR TACHYCARDIA: INSTITUTIONAL EXPERIENCE AND OUTCOMES
Authors: Konstantinos Siontis, Rakesh Latchamsetty, Miki Yokokawa, Krit Jongnarangsin, Fred Morady, Frank Bogun
Journal: Journal of the American College of Cardiology (2017)
ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer.
Authors: David E. Gerber, Geoffrey R. Oxnard, Sumithra J. Mandrekar, Suzanne Eleanor Dahlberg, Shakun M. Malik, Margaret M. Mooney, Jeffrey S. Abrams, Pasi A. Janne, Tianhong Li, Suresh S. Ramalingam, Everett E. Vokes, Ramaswamy Govindan
Journal: Journal of Clinical Oncology (2015)

TPS7583 Background: Molecularly targeted therapies, specifically those directed toward epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangement have improved outcomes in a subset of patients with advanced non-small cell lung cancer (NSCLC). However, the role of molecular testing and targeted therapies for earlier stage disease remains unclear. Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) is a National Cancer Institute (NCI) sponsored National Clinical Trials Network (NCTN) initiative to address these unanswered questions. Methods: ALCHEMIST is a clinical trial platform that currently consists of three integrated protocols: ALCHEMIST Screening (A151216; NCT02194738), ALCHEMIST-EGFR (A081105; NCT02193282), and ALCHEMIST-ALK (E4512; NCT02201992). In ALCHEMIST-Screening, up to 8,000 patients with pathologically confirmed stage IB ( ≥ 4 cm)-IIIA non-squamous NSCLC will be enrolled either before or after surgical resection. Tumors will be centrally genotyped for EGFR mutations and ALK rearrangements. Blood and tumor samples will also be collected for advanced genomic analysis at the NCI. Patients with EGFR mutations or ALK rearrangements will be referred to ALCHEMIST-EGFR or-ALK treatment trials, respectively. All other patients will be followed for relapse and survival. Available biopsies at recurrence will be collected to characterize clonal evolution. In the treatment trials, patients will be randomized to placebo vs. erlotinib or crizotinib after completion of standard adjuvant therapy. Treatment will continue for two years. Both trials are double blind studies with a primary endpoint of overall survival (OS). ALCHEMIST-EGFR will enroll 410 patients, which provides 85% power with one-sided type I error rate of 0.05 to demonstrate an OS hazard ratio (HR) of 0.67 favoring erlotinib. ALCHEMIST-ALK will enroll 378 patients to provide 80% power and one-sided type I error of 0.05 to demonstrate an OS HR of 0.67 favoring crizotinib. ALCHEMIST is currently enrolling patients at over 500 centers nationwide. Additional treatment trials for specific molecular subsets may be added in the future. Clinical trial information: NCT02194738.
Correlation of Bone Marrow Cellularity, Plasma Cell Infiltration and Microcirculation with Apparent Diffusion Coefficient of Diffusion Weighted Imaging In Patients with Monoclonal Plasma Cell Disease
Authors: Jens Hillengass, Bram Stieltjes, Tobias Baeuerle, Fabienne McClanahan, Christiane Heiss, Mindaugas Andrulis, Reiner Bartl, Rajiv Shah, Dirk Simon, Dirk Hose, Anthony D. Ho, Heinz Peter Schlemmer, Hartmut Goldschmidt, Stefan Delorme
Journal: Blood (2010)
LOW DOSE SYSTEMIC THROMBOLYSIS AND NEW ORAL ANTICOAGULANTS IN THE TREATMENT OF LARGE THROMBI IN THE RIGHT HEART
Authors: Mohsen Sharifi, Fatemeh Larijani, Ryan Wycliffe, Beth Loggins, Bethany Schroeder, Dana De Los Monteros, Wilbur Freeman
Journal: Journal of the American College of Cardiology (2017)
PROGNOSTIC VALUE OF SOLUBLE ST2 IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION
Authors: Pyung Chun Oh, Jongwook Yu, Kyunghee Byun, Myeongjoo Son, Minsu Kim, Soon Yong Suh, Kyounghoon Lee, Seung Hwan Han, Taehoon Ahn, Eak Kyun Shin, Woong Chol Kang
Journal: Journal of the American College of Cardiology (2017)
Combined Treatment with Lenalidomide (LEN) and Epoetin Alfa (EA) Is Superior to Lenalidomide Alone in Patients with Erythropoietin (Epo)-Refractory, Lower Risk (LR) Non-Deletion 5q [Del(5q)] Myelodysplastic Syndrome (MDS): Results of the E2905 Intergroup Study-an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health
Authors: Alan F List, Zhuoxin Sun, Amit Verma, John M. Bennett, Kathy L McGraw, Lisa Ann Nardelli, Jaroslaw P Maciejewski, Jessica K Altman, Puneet Cheema, David F. Claxton, Rami S. Komrokji, Selina Luger, Ryan Mattison, Tim Wassenaar, Andrew Artz, Charles A Schiffer, Martin S. Tallman
Journal: Blood (2016)
Laparoscopic transhiatal esophagectomy with neoadjuvant chemotherapy to treat carcinoma of the upper esophagus.
Authors: Ji-xiang Wu, Lei Yu, Jian-ye Li
Journal: Journal of Clinical Oncology (2013)

e15181 Background: Esophagectomy for Carcinoma of the upper esophagus has traditionally been performed by open methods. Results from most series include mortality rates in excess of 5% and hospital stays frequently greater than 14 days. Laparoscopic transhiatal esophagectomy (LTHE) with neoadjuvant chemotherapy has the potential to improve these results and may lead to a sound outcome, but only a few articles have reported it. The objective of this study is to investigate the method of LTHE with neoadjuvant chemotherapy treating cervical esophageal cancer. Methods: From 2011 to 2012, LTHE was performed in 15 patients with carcinoma of the upper esophagus. There were 11 men and 4 women. Median age was 64 years (range, 44–79). Indications for operation included high-grade dysplasia (n = 4) and cancer (n = 11). Neoadjuvant chemotherapy was used in 15 patients. Results: There was no conversion to open procedure. LTHE was successfully completed in 15 patients. The median intensive care unit stay was 1.5 days (range, 1–8); hospital stay was 10.5 days (range, 8–23). Anastomotic leak rate was 6.7% (n=1). At a mean follow-up of 13 months (range, 1–24), quality of life scores were similar to preoperative values and population norms. Conclusions: LTHE with neoadjuvant chemotherapy is a safe and relatively advanced, complex procedure with little blood loss and less-invasion. Its long-term outcome needs to be investigated with large-volume cases.